Melanotan Research History: From Peptides to Market Claims

The history of Melanotan is often told as a straight line from a laboratory discovery to a safe tanning product. The research is more varied. Different melanocortin analogues, clinical questions and product standards should not be collapsed into one claim.

Early pigment research

Work on alpha-melanocyte-stimulating hormone (alpha-MSH) and its analogues investigated pigmentation and melanocortin signalling. An early Melanotan II pilot study measured responses in a small group. A pilot study can identify questions for further research; it does not certify later online products or establish population-wide safety.

Do not confuse distinct analogues

A clinical review of afamelanotide describes another alpha-MSH analogue with its own development and clinical use. A finding or authorisation for one compound, formulation or indication cannot be transferred to Melanotan II sold under a similar name. Even a shared receptor pathway does not make the products interchangeable.

The market is a separate evidence question

The MHRA’s response on Melanotan II discusses the missing quality, safety and effectiveness safeguards for unauthorised products. Cancer Research UK advises against use of marketed Melanotan injections and nasal sprays. Our MSH terminology guide explains the hormone family; this history page covers the difference between research milestones and consumer claims.